A 26-year-old woman presents with 8 weeks of symmetric polyarthritis affecting hands, wrists, and feet with 90 minutes of morning stiffness. RF negative, anti-CCP negative, ANA 1:160 (homogeneous), ESR 45 mm/hr. She has no rash, oral ulcers, or systemic symptoms. Radiographs show soft tissue swelling without erosions. She desires pregnancy within the year. Apply the most appropriate initial management considering her reproductive plans.
Q2
A 58-year-old woman presents with bilateral shoulder and hip girdle pain and stiffness for 6 weeks. She has difficulty rising from a chair and combing her hair. ESR 72 mm/hr, CRP 6.8 mg/dL, CK normal, RF negative, ANA negative. She responds dramatically to prednisone 15 mg daily within 48 hours. Three months later, while tapering to 7.5 mg daily, she develops new-onset headache and scalp tenderness. ESR is now 85 mm/hr. Temporal artery biopsy shows non-specific inflammation. Apply the appropriate management modification.
Q3
A 50-year-old man with psoriatic arthritis on methotrexate 20 mg weekly presents with worsening polyarthritis despite 6 months of therapy. He has active dactylitis, enthesitis at Achilles insertion, and progressive erosive changes on hand radiographs. Liver enzymes are normal, creatinine 1.0 mg/dL. He also has moderate plaque psoriasis covering 15% body surface area. His insurance requires step therapy and has denied biologic coverage. Evaluate the most appropriate advocacy and management approach.
Q4
A 42-year-old man with ankylosing spondylitis on adalimumab for 2 years presents with progressive dyspnea. He is a non-smoker. PFTs show FVC 72% predicted, FEV1 78% predicted, FEV1/FVC 0.88, TLC 65% predicted. CT chest shows upper lobe fibrosis and cavitation. He also has new-onset heart block on ECG. Sputum cultures are negative for acid-fast bacilli after 3 samples. Analyze the most likely cause of his pulmonary and cardiac findings.
Q5
A 35-year-old woman with SLE on hydroxychloroquine and prednisone 10 mg daily presents at 10 weeks gestation with increased lupus disease activity including new-onset proteinuria (2 g/24h), arthritis, and rash. Labs show anti-dsDNA positive, low C3/C4, creatinine 1.2 mg/dL (baseline 0.8). Renal biopsy shows class III lupus nephritis. She desires to continue the pregnancy. Evaluate the optimal management strategy balancing maternal disease control and fetal safety.
Q6
A 68-year-old man presents with sudden onset severe headache, jaw claudication, and vision changes in his right eye. ESR is 98 mm/hr, CRP 8.5 mg/dL. Temporal artery is tender and non-pulsatile. Ophthalmology confirms anterior ischemic optic neuropathy. Temporal artery biopsy is scheduled for 3 days later. Apply the most appropriate immediate management.
Q7
A 45-year-old woman with systemic sclerosis (limited cutaneous type) presents with progressive dyspnea on exertion. She has had Raynaud's phenomenon for 15 years and skin thickening limited to hands and face. Pulmonary function tests show FVC 68% predicted, DLCO 52% predicted with preserved FEV1/FVC ratio. High-resolution CT chest shows ground-glass opacities and reticular changes in bilateral lower lobes. Right heart catheterization shows mean pulmonary artery pressure of 32 mmHg, pulmonary capillary wedge pressure 10 mmHg. Analyze the primary pulmonary complication and appropriate management.
Q8
A 55-year-old man with a 10-year history of rheumatoid arthritis on methotrexate and etanercept presents with sudden onset of right eye pain, redness, and photophobia. Visual acuity is decreased. Slit lamp examination reveals anterior chamber cells and flare. The patient also reports lower back stiffness worse in the morning that has developed over the past year. ESR is 42 mm/hr. HLA-B27 testing is positive. Analyze the most likely diagnosis and pathophysiologic relationship.
Q9
A 28-year-old African American woman presents with facial rash, arthralgia, and fatigue for 3 months. She has photosensitivity and oral ulcers. Labs show ANA 1:640 (speckled pattern), anti-dsDNA positive, anti-Smith antibody positive, complement C3 45 mg/dL (low), C4 8 mg/dL (low), WBC 3,200/μL, hemoglobin 10.2 g/dL, platelets 95,000/μL, creatinine 1.8 mg/dL. Urinalysis shows 3+ protein, RBC casts, and dysmorphic RBCs. Apply the most appropriate next diagnostic step.
Q10
A 32-year-old woman presents with a 6-week history of symmetric joint pain and swelling affecting her wrists, metacarpophalangeal joints, and proximal interphalangeal joints. She reports 2 hours of morning stiffness that improves with activity. Physical examination reveals warm, tender, swollen joints bilaterally. Laboratory studies show rheumatoid factor positive (1:320), anti-CCP antibody 180 U/mL (normal <20), ESR 65 mm/hr, and CRP 4.2 mg/dL. Apply the appropriate initial management strategy.
Rheumatology (autoimmune diseases, arthritis) US Medical PG Practice Questions and MCQs
Question 1: A 26-year-old woman presents with 8 weeks of symmetric polyarthritis affecting hands, wrists, and feet with 90 minutes of morning stiffness. RF negative, anti-CCP negative, ANA 1:160 (homogeneous), ESR 45 mm/hr. She has no rash, oral ulcers, or systemic symptoms. Radiographs show soft tissue swelling without erosions. She desires pregnancy within the year. Apply the most appropriate initial management considering her reproductive plans.
A. Defer DMARD therapy until after pregnancy to avoid any fetal risk
B. Initiate sulfasalazine given safety profile in pregnancy
C. Start combination hydroxychloroquine and sulfasalazine for adequate disease control (Correct Answer)
D. Begin hydroxychloroquine as pregnancy-compatible DMARD
E. Start methotrexate with strict contraception counseling; switch when ready to conceive
Explanation: ***Start combination hydroxychloroquine and sulfasalazine for adequate disease control***
- This patient presents with **symmetric polyarthritis** and an elevated **ANA**, suggesting an early connective tissue disease or seronegative RA; the combination of **hydroxychloroquine and sulfasalazine** is the best choice for achieving remission while ensuring safety for **future pregnancy**.
- Both medications are considered **Category B/C** but are standard of care in pregnancy-compatible DMARD regimens to prevent joint damage and systemic flares.
*Start methotrexate with strict contraception counseling; switch when ready to conceive*
- **Methotrexate** is absolutely **teratogenic** and must be discontinued at least 3 months prior to conception, making it suboptimal for someone wanting to conceive within the year.
- Starting a known teratogen when a patient has active pregnancy plans within a short window increases the risk of **accidental fetal exposure**.
*Begin hydroxychloroquine as pregnancy-compatible DMARD*
- While **hydroxychloroquine** is safe in pregnancy, monotherapy may be insufficient to control **symmetric polyarthritis** with significant inflammatory markers (**ESR 45**).
- A more robust initial approach with **combination therapy** is often preferred to quickly suppress inflammation before the patient conceives.
*Initiate sulfasalazine given safety profile in pregnancy*
- **Sulfasalazine** is safe in pregnancy (with folic acid supplementation), but as monotherapy, it may not provide adequate control for **ANA-positive** inflammatory arthritis.
- Utilizing a single agent risks **persistent disease activity**, which itself is associated with poorer pregnancy outcomes compared to well-controlled disease.
*Defer DMARD therapy until after pregnancy to avoid any fetal risk*
- Deferring treatment is inappropriate as active **maternal inflammation** increases the risk of **preterm birth** and low birth weight.
- Non-erosive arthritis can progress to **irreversible joint damage** if left untreated for the duration of a pregnancy and postpartum period.
Question 2: A 58-year-old woman presents with bilateral shoulder and hip girdle pain and stiffness for 6 weeks. She has difficulty rising from a chair and combing her hair. ESR 72 mm/hr, CRP 6.8 mg/dL, CK normal, RF negative, ANA negative. She responds dramatically to prednisone 15 mg daily within 48 hours. Three months later, while tapering to 7.5 mg daily, she develops new-onset headache and scalp tenderness. ESR is now 85 mm/hr. Temporal artery biopsy shows non-specific inflammation. Apply the appropriate management modification.
A. Continue prednisone taper as planned; biopsy does not confirm GCA
B. Repeat temporal artery biopsy on contralateral side before treatment modification
C. Switch to tocilizumab as biopsy-negative GCA
D. Add methotrexate to current prednisone dose as steroid-sparing agent
E. Increase prednisone to 40-60 mg daily based on clinical suspicion despite negative biopsy (Correct Answer)
Explanation: ***Increase prednisone to 40-60 mg daily based on clinical suspicion despite negative biopsy***
- The patient presents with classic **Giant Cell Arteritis (GCA)** symptoms (headache, scalp tenderness) and a high **ESR**, which demands immediate high-dose corticosteroids to prevent **permanent vision loss**.
- A **negative temporal artery biopsy** does not exclude the diagnosis due to **skip lesions**; management should be guided by the high **pre-test probability** and clinical presentation following **Polymyalgia Rheumatica (PMR)**.
*Continue prednisone taper as planned; biopsy does not confirm GCA*
- Stopping or continuing a low-dose taper in a patient with active cranial symptoms of **vasculitis** is dangerous and increases the risk of **blindness**.
- Clinical judgment must override a negative biopsy when symptoms of **GCA** are as overt as **scalp tenderness** and a significantly elevated **ESR**.
*Switch to tocilizumab as biopsy-negative GCA*
- **Tocilizumab** is an FDA-approved IL-6 inhibitor for GCA, but it is typically used in combination with **prednisone**, not as a monotherapy replacement during an acute symptomatic flare.
- High-dose **glucocorticoids** are the immediate first-line treatment required to rapidly suppress vascular inflammation and prevent ischemic complications.
*Add methotrexate to current prednisone dose as steroid-sparing agent*
- **Methotrexate** is used as a steroid-sparing agent in GCA/PMR maintenance but does not act quickly enough to manage an acute flare with **cranial symptoms**.
- The priority is to escalate the **prednisone** dose to controlled levels (40-60 mg) before considering adjunctive steroid-sparing therapies.
*Repeat temporal artery biopsy on contralateral side before treatment modification*
- While a **contralateral biopsy** may increase yield, treatment modification with **high-dose steroids** must happen immediately and should not be delayed for further diagnostic testing.
- Delaying the start of 40-60 mg of prednisone while waiting for another surgical procedure risks irreversible **ischemic optic neuropathy**.
Question 3: A 50-year-old man with psoriatic arthritis on methotrexate 20 mg weekly presents with worsening polyarthritis despite 6 months of therapy. He has active dactylitis, enthesitis at Achilles insertion, and progressive erosive changes on hand radiographs. Liver enzymes are normal, creatinine 1.0 mg/dL. He also has moderate plaque psoriasis covering 15% body surface area. His insurance requires step therapy and has denied biologic coverage. Evaluate the most appropriate advocacy and management approach.
A. Increase methotrexate to 25 mg weekly and add leflunomide for combination DMARD therapy
B. Add systemic corticosteroids long-term while continuing insurance appeals
C. Document treatment failure with objective measures and peer-to-peer review to justify biologic therapy (Correct Answer)
D. Switch to leflunomide monotherapy as alternative to biologic
E. Add sulfasalazine to methotrexate while appealing insurance denial with documentation of inadequate response
Explanation: ***Document treatment failure with objective measures and peer-to-peer review to justify biologic therapy***
- In **psoriatic arthritis (PsA)** with **progressive erosive disease**, dactylitis, and enthesitis, the preferred move is to escalate to a **biologic DMARD (bDMARD)** as conventional DMARDs like **methotrexate** often fail to prevent radiographic damage.
- Using objective data (e.g., **radiographic erosions**, **BSA** for psoriasis) during a **peer-to-peer review** is the standard advocacy step to bypass "fail first" policies when clinical deterioration is evident.
*Increase methotrexate to 25 mg weekly and add leflunomide for combination DMARD therapy*
- While **methotrexate** can be titrated to 25 mg, **combination csDMARD therapy** has not been shown to be as effective as **biologics** in halting **radiographic progression** or managing severe **enthesitis**.
- Adding **leflunomide** increases the risk of **hepatotoxicity** without providing the superior efficacy needed for this patient's high-risk features and skin involvement.
*Add sulfasalazine to methotrexate while appealing insurance denial with documentation of inadequate response*
- **Sulfasalazine** is a weaker **conventional synthetic DMARD (csDMARD)** that is generally ineffective for the patient's **enthesitis** and **psoriatic skin lesions**.
- Delaying the initiation of a **biologic** by introducing another csDMARD risks further **joint destruction** and functional impairment in a patient already showing **erosive changes**.
*Switch to leflunomide monotherapy as alternative to biologic*
- Switching from one **csDMARD** to another (e.g., methotrexate to **leflunomide**) is rarely successful when there is already an inadequate response and **erosive progression**.
- **Leflunomide** does not provide the same level of protection against **joint damage** or the high clearance of **plaque psoriasis** seen with **TNF** or **IL-17 inhibitors**.
*Add systemic corticosteroids long-term while continuing insurance appeals*
- **Systemic corticosteroids** should be avoided long-term in **PsA** because tapering can trigger life-threatening **erythrodermic** or **pustular psoriasis flare-ups**.
- They do not address the underlying **disease progression** or **erosions** and carry significant side effects like osteoporosis and metabolic syndrome.
Question 4: A 42-year-old man with ankylosing spondylitis on adalimumab for 2 years presents with progressive dyspnea. He is a non-smoker. PFTs show FVC 72% predicted, FEV1 78% predicted, FEV1/FVC 0.88, TLC 65% predicted. CT chest shows upper lobe fibrosis and cavitation. He also has new-onset heart block on ECG. Sputum cultures are negative for acid-fast bacilli after 3 samples. Analyze the most likely cause of his pulmonary and cardiac findings.
A. Ankylosing spondylitis pulmonary manifestation with conduction system disease (Correct Answer)
B. Adalimumab-induced tuberculosis reactivation with cardiac involvement
C. Atypical mycobacterial infection with endocarditis
D. Adalimumab-induced interstitial lung disease and cardiomyopathy
E. Sarcoidosis mimicking AS with multi-organ involvement
Explanation: ***Ankylosing spondylitis pulmonary manifestation with conduction system disease***
- **Ankylosing spondylitis (AS)** can cause extra-articular manifestations including **apical pulmonary fibrosis** and **cavitation** which present as a **restrictive lung disease** pattern.
- Cardiac involvement in AS includes **aortitis** and **fibrosis of the conduction system**, which can manifest as **heart block** and valvular dysfunction.
*Adalimumab-induced tuberculosis reactivation with cardiac involvement*
- While **TNF-alpha inhibitors** like adalimumab increase **tuberculosis** risk, this patient had three **negative AFB sputum cultures**, making active TB less likely.
- TB usually presents with systemic symptoms like **weight loss and night sweats**, and it does not typically cause cardiac **conduction system disease** indirectly.
*Adalimumab-induced interstitial lung disease and cardiomyopathy*
- **Drug-induced ILD** from biologics usually presents with a **diffuse or basal** pattern rather than the **upper lobe fibrosis** specific to AS.
- Biologics are more likely to worsen pre-existing **congestive heart failure** rather than causing isolated **new-onset heart block** in this demographic.
*Sarcoidosis mimicking AS with multi-organ involvement*
- **Sarcoidosis** can cause upper lobe disease and heart block, but the patient has a **2-year history of AS** and is on directed therapy, making AS-related complications more probable.
- Sarcoidosis typically presents with **hilar lymphadenopathy** on CT, which was not mentioned in this clinical presentation.
*Atypical mycobacterial infection with endocarditis*
- **Atypical mycobacteria** can colonize AS lung cavities, but negative cultures and the specific **conduction block** point toward an inflammatory AS process.
- **Endocarditis** would typically present with **fever**, murmurs, and embolic phenomena rather than isolated **heart block** and restrictive lung findings.
Question 5: A 35-year-old woman with SLE on hydroxychloroquine and prednisone 10 mg daily presents at 10 weeks gestation with increased lupus disease activity including new-onset proteinuria (2 g/24h), arthritis, and rash. Labs show anti-dsDNA positive, low C3/C4, creatinine 1.2 mg/dL (baseline 0.8). Renal biopsy shows class III lupus nephritis. She desires to continue the pregnancy. Evaluate the optimal management strategy balancing maternal disease control and fetal safety.
A. Increase prednisone to 60 mg daily as monotherapy throughout pregnancy
B. Continue current therapy and monitor closely; avoid additional immunosuppression during pregnancy
C. Terminate pregnancy and start cyclophosphamide for aggressive disease
D. Add azathioprine as steroid-sparing agent with hydroxychloroquine continuation (Correct Answer)
E. Initiate mycophenolate mofetil given severity of nephritis
Explanation: ***Add azathioprine as steroid-sparing agent with hydroxychloroquine continuation***
- **Azathioprine** is the induction and maintenance agent of choice for **lupus nephritis** during pregnancy as it is the most well-studied, pregnancy-compatible immunosuppressant.
- Continuation of **hydroxychloroquine** is essential as it reduces **disease flares** and the risk of **neonatal lupus** or congenital heart block.
*Continue current therapy and monitor closely; avoid additional immunosuppression during pregnancy*
- Passive monitoring is insufficient for **active Class III lupus nephritis**, which carries a high risk of **progression to renal failure** and adverse pregnancy outcomes like preeclampsia.
- New-onset **proteinuria** and rising **creatinine** signify an acute flare that requires intensified treatment beyond low-dose prednisone.
*Increase prednisone to 60 mg daily as monotherapy throughout pregnancy*
- Long-term **high-dose glucocorticoids** significantly increase risks of **gestational diabetes**, maternal hypertension, and **premature rupture of membranes**.
- Steroids alone may not be sufficient to maintain remission in **proliferative lupus nephritis** without a steroid-sparing agent like azathioprine.
*Initiate mycophenolate mofetil given severity of nephritis*
- **Mycophenolate mofetil** is a known **teratogen** (FDA Category D) and is strictly contraindicated due to the risk of **mycophenolate embryopathy** and spontaneous abortion.
- It should be discontinued at least **6 weeks prior to conception** and never initiated during the first trimester.
*Terminate pregnancy and start cyclophosphamide for aggressive disease*
- **Cyclophosphamide** is highly **teratogenic**, especially in the first trimester, but pregnancy termination is not mandatory for **Class III lupus nephritis** as pregnancy-safe alternatives exist.
- Termination is typically reserved for **life-threatening maternal complications** or severe, refractory organ failure that cannot be managed with compatible medications.
Question 6: A 68-year-old man presents with sudden onset severe headache, jaw claudication, and vision changes in his right eye. ESR is 98 mm/hr, CRP 8.5 mg/dL. Temporal artery is tender and non-pulsatile. Ophthalmology confirms anterior ischemic optic neuropathy. Temporal artery biopsy is scheduled for 3 days later. Apply the most appropriate immediate management.
A. Start oral prednisone 60 mg daily immediately, proceed with biopsy as scheduled
B. Wait for biopsy confirmation before starting treatment to avoid false-negative results
C. Start methotrexate as steroid-sparing agent with low-dose prednisone
D. Begin intravenous methylprednisolone 1000 mg daily for 3 days, then oral prednisone (Correct Answer)
E. Initiate aspirin and statin therapy, defer steroids until biopsy proven
Explanation: ***Begin intravenous methylprednisolone 1000 mg daily for 3 days, then oral prednisone***
- This patient presents with **Giant Cell Arteritis (GCA)** complicated by **vision loss (anterior ischemic optic neuropathy)**, which is a medical emergency requiring **high-dose intravenous pulse steroids** to prevent further visual impairment.
- Immediate management is critical to protect the remaining vision and the **contralateral eye**, as the risk of bilateral blindness is high if left untreated.
*Wait for biopsy confirmation before starting treatment to avoid false-negative results*
- **Glucocorticoids** should never be withheld while awaiting a biopsy, as **permanent blindness** can occur within hours if the inflammation is not suppressed.
- A **temporal artery biopsy** remains diagnostically useful for up to 1-2 weeks after initiating steroids, so early treatment does not immediately result in a false-negative.
*Start oral prednisone 60 mg daily immediately, proceed with biopsy as scheduled*
- Although oral prednisone (1 mg/kg or 40-60 mg) is standard for GCA without complications, **intravenous pulse therapy** is indicated when **visual loss** or **neurological deficits** have already occurred.
- Oral therapy may have insufficient bioavailability or speed of action in the acute phase of **ocular ischemia** compared to IV methylprednisolone.
*Initiate aspirin and statin therapy, defer steroids until biopsy proven*
- Deferring steroids in a patient with a high clinical suspicion of GCA and elevated inflammatory markers (**ESR 98 mm/hr**) is negligent due to the extreme risk of **irreversible blindness**.
- While **aspirin** may be added to reduce strokes, it does not treat the underlying **large vessel vasculitis** or prevent the progression of optic nerve ischemia.
*Start methotrexate as steroid-sparing agent with low-dose prednisone*
- **Methotrexate** is an adjunctive therapy used to reduce cumulative steroid dose in the long term, but it has no role in the **acute management** of GCA symptoms.
- **Low-dose prednisone** is completely inadequate for suppressing the severe **granulomatous inflammation** associated with temporal arteritis and visual loss.
Question 7: A 45-year-old woman with systemic sclerosis (limited cutaneous type) presents with progressive dyspnea on exertion. She has had Raynaud's phenomenon for 15 years and skin thickening limited to hands and face. Pulmonary function tests show FVC 68% predicted, DLCO 52% predicted with preserved FEV1/FVC ratio. High-resolution CT chest shows ground-glass opacities and reticular changes in bilateral lower lobes. Right heart catheterization shows mean pulmonary artery pressure of 32 mmHg, pulmonary capillary wedge pressure 10 mmHg. Analyze the primary pulmonary complication and appropriate management.
A. Interstitial lung disease; treat with mycophenolate or cyclophosphamide
B. Pulmonary arterial hypertension; treat with endothelin receptor antagonist
C. Pulmonary veno-occlusive disease; list for lung transplantation
D. Combined pulmonary fibrosis and pulmonary hypertension; treat both conditions (Correct Answer)
E. Restrictive lung disease from chest wall involvement; supportive care only
Explanation: ***Combined pulmonary fibrosis and pulmonary hypertension; treat both conditions***
- The patient exhibits evidence of **Interstitial Lung Disease (ILD)** via **reticular changes** on HRCT and a low FVC, alongside **Pulmonary Hypertension (PH)** confirmed by a **mean pulmonary artery pressure (mPAP)** of 32 mmHg.
- Management must address both the parenchymal fibrosis (often with immunosuppressants like **mycophenolate**) and the vascular component if the PH is significant, reflecting the multi-organ involvement of **Systemic Sclerosis**.
*Pulmonary arterial hypertension; treat with endothelin receptor antagonist*
- Isolated **Pulmonary Arterial Hypertension (Group 1)** is common in the limited subtype but typically presents with **normal FVC** and clear imaging on **HRCT**.
- Treating with vasoactive agents like **ERAs** without addressing the underlying **restrictive lung disease** seen on her CT would be incomplete clinical management.
*Interstitial lung disease; treat with mycophenolate or cyclophosphamide*
- While the patient clearly has **ILD** as evidenced by **ground-glass opacities**, this diagnosis alone does not account for the **elevated mPAP** found on catheterization.
- Focusing solely on **immunosuppression** ignores the hemodynamic complication of **Group 3 PH**, which significantly impacts prognosis and functional status.
*Restrictive lung disease from chest wall involvement; supportive care only*
- Although skin thickening can cause restriction, the presence of **parenchymal changes** on HRCT and a **low DLCO** confirm intrinsic lung disease rather than simple external restriction.
- **Supportive care only** is inappropriate because medications like **mycophenolate mofetil** are proven to slow the progression of Scleroderma-related lung disease.
*Pulmonary veno-occlusive disease; list for lung transplantation*
- **PVOD** is a rare complication that presents with severe PH and signs of **pulmonary edema** on CT (like septal lines) despite a normal wedge pressure.
- While transplantation is a final option, the imaging and PFTs specifically point toward **Systemic Sclerosis-associated ILD**, which has established pharmacological treatment pathways.
Question 8: A 55-year-old man with a 10-year history of rheumatoid arthritis on methotrexate and etanercept presents with sudden onset of right eye pain, redness, and photophobia. Visual acuity is decreased. Slit lamp examination reveals anterior chamber cells and flare. The patient also reports lower back stiffness worse in the morning that has developed over the past year. ESR is 42 mm/hr. HLA-B27 testing is positive. Analyze the most likely diagnosis and pathophysiologic relationship.
A. Coexisting HLA-B27-associated anterior uveitis unrelated to RA (Correct Answer)
B. Rheumatoid vasculitis affecting the uveal tract
C. Methotrexate-induced uveitis as a medication side effect
D. Etanercept-induced autoimmune uveitis
E. Infectious endophthalmitis from immunosuppression
Explanation: ***Coexisting HLA-B27-associated anterior uveitis unrelated to RA***
- The patient's presentation of **sudden eye pain**, **photophobia**, **decreased visual acuity**, and **anterior chamber cells/flare** describes **acute anterior uveitis**, the most common extra-axial manifestation of **HLA-B27 spondyloarthropathies**.
- Lower back stiffness that is **worse in the morning** (inflammatory back pain) combined with **HLA-B27 positivity** suggests a diagnosis of **Ankylosing Spondylitis**, which can coexist with, but is pathophysiologically distinct from, **Rheumatoid Arthritis**.
*Methotrexate-induced uveitis as a medication side effect*
- **Methotrexate** is frequently used to *treat* uveitis; it is not known to be a causative agent for **acute anterior uveitis**.
- This option ignores the clinical significance of the **positive HLA-B27** and the new-onset **inflammatory back pain**.
*Infectious endophthalmitis from immunosuppression*
- **Endophthalmitis** usually occurs following trauma or intraocular surgery and presents with severe vision loss and **vitreous involvement**, which is not described.
- While the patient is on **methotrexate** and **etanercept**, the localized **anterior chamber** findings and back pain are more consistent with an **autoimmune spondyloarthropathy**.
*Rheumatoid vasculitis affecting the uveal tract*
- **Rheumatoid vasculitis** is a complication of long-standing RA but typically affects the skin (ulcers), nerves (mononeuritis multiplex), or **sclera** (scleritis), not the uvea.
- RA-related spinal disease is classically limited to the **cervical spine** (atlantoaxial subluxation) and does not explain low back stiffness or **HLA-B27** positivity.
*Etanercept-induced autoimmune uveitis*
- Some **TNF-alpha inhibitors**, particularly **etanercept**, have been paradoxically linked to **de novo uveitis**, but etanercept is less effective at treating uveitis than monoclonal antibodies like adalimumab.
- This diagnosis is less likely than **HLA-B27-associated uveitis** given the classic triad of inflammatory back pain, positive genetic marker, and acute eye symptoms.
Question 9: A 28-year-old African American woman presents with facial rash, arthralgia, and fatigue for 3 months. She has photosensitivity and oral ulcers. Labs show ANA 1:640 (speckled pattern), anti-dsDNA positive, anti-Smith antibody positive, complement C3 45 mg/dL (low), C4 8 mg/dL (low), WBC 3,200/μL, hemoglobin 10.2 g/dL, platelets 95,000/μL, creatinine 1.8 mg/dL. Urinalysis shows 3+ protein, RBC casts, and dysmorphic RBCs. Apply the most appropriate next diagnostic step.
A. Perform renal biopsy to determine class of lupus nephritis (Correct Answer)
B. Order anti-phospholipid antibody panel and defer kidney evaluation
C. Start hydroxychloroquine and reassess in 4 weeks
D. Initiate cyclophosphamide based on laboratory findings alone
E. Begin high-dose corticosteroids immediately without further testing
Explanation: ***Perform renal biopsy to determine class of lupus nephritis***
- The presence of **proteinuria, RBC casts, and dysmorphic RBCs** in a patient with SLE strongly indicates active **lupus nephritis**, which requires a biopsy to classify the disease according to **ISN/RPS criteria**.
- A biopsy is essential to differentiate between **proliferative (Class III/IV)** and **membranous (Class V)** patterns, as this directly determines the intensity of **immunosuppressive therapy** needed.
*Start hydroxychloroquine and reassess in 4 weeks*
- Hydroxychloroquine is a cornerstone for treating **systemic SLE** and preventing flares, but it is insufficient as a standalone treatment for active **nephritic syndrome**.
- Delaying the evaluation of **renal dysfunction** (evidenced by elevated creatinine) for 4 weeks could lead to irreversible **glomerular scarring** and permanent renal failure.
*Begin high-dose corticosteroids immediately without further testing*
- While steroids are often part of the treatment, the exact **induction regimen** and the need for additional agents like **mycophenolate** or **cyclophosphamide** depend on the biopsy findings.
- High-dose steroids possess significant **systemic toxicity**, and their use should be justified by histopathological evidence of **active inflammatory lesions** rather than chronicity.
*Order anti-phospholipid antibody panel and defer kidney evaluation*
- An **anti-phospholipid panel** is appropriate to screen for **venous thromboembolism** or pregnancy risk, but it does not address the patient's acute **nephritic sediment**.
- Deferring the kidney evaluation is dangerous, as **lupus nephritis** is a major cause of morbidity and must be categorized to prevent progression to **end-stage renal disease (ESRD)**.
*Initiate cyclophosphamide based on laboratory findings alone*
- Cyclophosphamide is a highly toxic **cytotoxic agent** with risks of **infertility** and **malignancy**, so it should not be started without confirming a proliferative class via **histopathology**.
- Lab markers like low **C3 and C4** or positive **anti-dsDNA** correlate with disease activity but do not provide the definitive morphological diagnosis required for such aggressive therapy.
Question 10: A 32-year-old woman presents with a 6-week history of symmetric joint pain and swelling affecting her wrists, metacarpophalangeal joints, and proximal interphalangeal joints. She reports 2 hours of morning stiffness that improves with activity. Physical examination reveals warm, tender, swollen joints bilaterally. Laboratory studies show rheumatoid factor positive (1:320), anti-CCP antibody 180 U/mL (normal <20), ESR 65 mm/hr, and CRP 4.2 mg/dL. Apply the appropriate initial management strategy.
A. Begin methotrexate with folic acid supplementation and short-term low-dose prednisone bridge (Correct Answer)
B. Initiate biologic therapy with anti-TNF agent as first-line treatment
C. Start high-dose prednisone alone and reassess in 3 months
D. Prescribe NSAIDs and physical therapy, defer DMARDs until radiographic changes appear
E. Start hydroxychloroquine monotherapy
Explanation: ***Begin methotrexate with folic acid supplementation and short-term low-dose prednisone bridge***
- **Methotrexate** is the gold-standard first-line **csDMARD** for rheumatoid arthritis, and **folic acid** is essential to reduce its gastrointestinal and hematologic side effects.
- **Low-dose prednisone** serves as a temporary **bridge therapy** to provide rapid symptomatic relief while waiting 6 to 12 weeks for methotrexate to reach full clinical efficacy.
*Start high-dose prednisone alone and reassess in 3 months*
- Using **monotherapy with steroids** is discouraged because it does not stop joint destruction and leads to significant long-term **toxicities** like osteoporosis and hyperglycemia.
- Rheumatoid arthritis management requires early initiation of **DMARDs** to prevent irreversible **radiographic damage**, which steroids alone cannot achieve.
*Start hydroxychloroquine monotherapy*
- **Hydroxychloroquine** is a mild DMARD typically reserved for very **mild disease** or as part of combination therapy; it is often insufficient for patients with high-titer **anti-CCP** and multiple swollen joints.
- This patient exhibits high disease activity and poor prognostic factors, necessitating more potent therapy like **methotrexate** to achieve remission.
*Initiate biologic therapy with anti-TNF agent as first-line treatment*
- **TNF inhibitors** are generally not indicated as initial therapy unless there is a contraindication or failure of an adequate trial of **conventional synthetic DMARDs**.
- Most clinical guidelines recommend a **step-up approach** due to the high cost and potential for serious **infections** associated with biologic agents.
*Prescribe NSAIDs and physical therapy, defer DMARDs until radiographic changes appear*
- **NSAIDs** only manage pain and do not modify the disease course; waiting for **radiographic changes** means allowing permanent, irreversible joint damage to occur.
- The current "treat-to-target" strategy emphasizes starting **DMARDs** as soon as the diagnosis is made to capitalize on the **window of opportunity** for better long-term outcomes.
